Literature DB >> 17763202

The clinical role of IL-23p19 in patients with rheumatoid arthritis.

H-R Kim1, H-S Kim, M-K Park, M-L Cho, S-H Lee, H-Y Kim.   

Abstract

OBJECTIVE: To determine the clinical implications of the over-expression of synovial and circulating interleukin (IL)-23p19 and the correlation between IL-23p19 and other cytokines such as IL-17, tumour necrosis factor (TNF)alpha, and IL-1beta in rheumatoid arthritis (RA).
METHODS: Synovial fluid (SF) and sera of 22 patients with RA were obtained during knee arthrocentesis and stored at -20 degrees C. Tender/swollen joint counts, 100-mm visual analogue scale (VAS), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF), and antibodies to cyclic citrullinated peptide (anti-CCP Ab) were measured. Bony erosions were determined by X-rays. Serum and SF IL-23p19, IL-17, TNFalpha, and IL-1beta concentrations were measured by sandwich enzyme-linked immunosorbent assay (ELISA).
RESULTS: The concentration of IL-23p19 correlated with the concentration of IL-17 in SF and sera, and with the concentrations of TNFalpha and IL-1beta in sera. SF IL-23p19 concentration was higher in patients who had bony erosions than those who had not. However, there was no correlation between IL-23p19 concentrations and other clinical parameters of RA.
CONCLUSION: Upregulated IL-23p19 in SF might be involved in joint destruction in RA through interplay with other cytokines such as IL-17, TNFalpha, and IL-1beta.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17763202     DOI: 10.1080/03009740701286813

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  23 in total

Review 1.  A cytokine-centric view of the pathogenesis and treatment of autoimmune arthritis.

Authors:  Brian Astry; Erin Harberts; Kamal D Moudgil
Journal:  J Interferon Cytokine Res       Date:  2011-12       Impact factor: 2.607

2.  Posttranscriptional regulation of IL-23 expression by IFN-gamma through tristetraprolin.

Authors:  Xuesong Qian; Huan Ning; Jidong Zhang; Daniel F Hoft; Deborah J Stumpo; Perry J Blackshear; Jianguo Liu
Journal:  J Immunol       Date:  2011-04-22       Impact factor: 5.422

Review 3.  New complexities in helper T cell fate determination and the implications for autoimmune diseases.

Authors:  Hiroaki Takatori; Yuka Kanno; Zhi Chen; John J O'Shea
Journal:  Mod Rheumatol       Date:  2008-08-05       Impact factor: 3.023

Review 4.  Interleukin-23 as a potential therapeutic target for rheumatoid arthritis.

Authors:  Chao Rong; Wei Hu; Fan-rong Wu; Xiao-juan Cao; Fei-hu Chen
Journal:  Mol Cell Biochem       Date:  2011-10-20       Impact factor: 3.396

Review 5.  Interleukin-23: as a drug target for autoimmune inflammatory diseases.

Authors:  Chunlei Tang; Shu Chen; Hai Qian; Wenlong Huang
Journal:  Immunology       Date:  2012-02       Impact factor: 7.397

Review 6.  Possible roles of IL-12-family cytokines in rheumatoid arthritis.

Authors:  Richard M Pope; Shiva Shahrara
Journal:  Nat Rev Rheumatol       Date:  2012-10-23       Impact factor: 20.543

7.  Serum and synovial fluid levels of p40 IL12/23 in spondyloarthropathy patients.

Authors:  Daniel Wendling; Jean-Pierre Cedoz; Evelyne Racadot
Journal:  Clin Rheumatol       Date:  2008-09-27       Impact factor: 2.980

8.  IL-12p40 Homodimer Ameliorates Experimental Autoimmune Arthritis.

Authors:  Seon-Yeong Lee; Young Ok Jung; Doo-Jin Kim; Chang-Min Kang; Young-Mee Moon; Yu-Jung Heo; Hye-Jwa Oh; Seong-Jeong Park; Se-Hwan Yang; Seung Ki Kwok; Ji-Hyeon Ju; Sung-Hwan Park; Young Chul Sung; Ho-Youn Kim; Mi-La Cho
Journal:  J Immunol       Date:  2015-08-31       Impact factor: 5.422

Review 9.  The role of T helper type 17 cells in inflammatory arthritis.

Authors:  S Sarkar; L A Cooney; D A Fox
Journal:  Clin Exp Immunol       Date:  2009-08-25       Impact factor: 4.330

10.  Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies.

Authors:  Ellen M Moran; Ronan Mullan; Jennifer McCormick; Mary Connolly; Owen Sullivan; Oliver Fitzgerald; Barry Bresnihan; Douglas J Veale; Ursula Fearon
Journal:  Arthritis Res Ther       Date:  2009-07-23       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.